A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
Sponsor: Eli Lilly and Company
This PHASE3 trial investigates Medullary Thyroid Cancer and is currently ongoing. Eli Lilly and Company leads this study, which shows 44 recorded versions since 2020 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
44 versions recorded-
Sep 2025 — Present [monthly]
Active Not Recruiting PHASE3
-
May 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE3
-
Mar 2025 — May 2025 [monthly]
Active Not Recruiting PHASE3
-
Sep 2024 — Mar 2025 [monthly]
Active Not Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE3
▶ Show 39 earlier versions
-
Feb 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE3
-
Nov 2023 — Feb 2024 [monthly]
Active Not Recruiting PHASE3
-
Sep 2023 — Nov 2023 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Aug 2023 — Sep 2023 [monthly]
Recruiting PHASE3
-
Jun 2023 — Aug 2023 [monthly]
Recruiting PHASE3
-
May 2023 — Jun 2023 [monthly]
Recruiting PHASE3
-
Apr 2023 — May 2023 [monthly]
Recruiting PHASE3
-
Mar 2023 — Apr 2023 [monthly]
Recruiting PHASE3
-
Feb 2023 — Mar 2023 [monthly]
Recruiting PHASE3
-
Jan 2023 — Feb 2023 [monthly]
Recruiting PHASE3
-
Dec 2022 — Jan 2023 [monthly]
Recruiting PHASE3
-
Nov 2022 — Dec 2022 [monthly]
Recruiting PHASE3
-
Sep 2022 — Nov 2022 [monthly]
Recruiting PHASE3
-
Jul 2022 — Sep 2022 [monthly]
Recruiting PHASE3
-
Jun 2022 — Jul 2022 [monthly]
Recruiting PHASE3
-
May 2022 — Jun 2022 [monthly]
Recruiting PHASE3
-
Apr 2022 — May 2022 [monthly]
Recruiting PHASE3
-
Jan 2022 — Apr 2022 [monthly]
Recruiting PHASE3
-
Dec 2021 — Jan 2022 [monthly]
Recruiting PHASE3
-
Nov 2021 — Dec 2021 [monthly]
Recruiting PHASE3
-
Oct 2021 — Nov 2021 [monthly]
Recruiting PHASE3
-
Sep 2021 — Oct 2021 [monthly]
Recruiting PHASE3
-
Jun 2021 — Sep 2021 [monthly]
Recruiting PHASE3
-
May 2021 — Jun 2021 [monthly]
Recruiting PHASE3
-
Apr 2021 — May 2021 [monthly]
Recruiting PHASE3
-
Mar 2021 — Apr 2021 [monthly]
Recruiting PHASE3
-
Feb 2021 — Mar 2021 [monthly]
Recruiting PHASE3
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE3
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE3
-
Nov 2020 — Dec 2020 [monthly]
Recruiting PHASE3
-
Oct 2020 — Nov 2020 [monthly]
Recruiting PHASE3
-
Sep 2020 — Oct 2020 [monthly]
Recruiting PHASE3
-
Aug 2020 — Sep 2020 [monthly]
Recruiting PHASE3
-
Jul 2020 — Aug 2020 [monthly]
Recruiting PHASE3
-
Jun 2020 — Jul 2020 [monthly]
Recruiting PHASE3
-
May 2020 — Jun 2020 [monthly]
Recruiting PHASE3
-
Apr 2020 — May 2020 [monthly]
Recruiting PHASE3
-
Mar 2020 — Apr 2020 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Jan 2020 — Mar 2020 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Eli Lilly and Company
- Loxo Oncology, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Amsterdam, Netherlands , Angers, France , Ann Arbor, United States , Athens, Greece , Atlanta, United States , Barcelona, Spain , Barretos, Brazil , Beijing, China , Belo Horizonte, Brazil , Berlin, Germany and 110 more locations